To hear about similar clinical trials, please enter your email below
Trial Title:
Galectin-3 in Papillary Thyroid Carcinoma
NCT ID:
NCT05699590
Condition:
Galactin 3-thyroid Carcinoma
Conditions: Official terms:
Carcinoma
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Summary:
Thyroid cancer is a common head and neck malignancy. It is the most common endocrine
tumor in the body accounting for 1% of all cancers worldwide. The incidence of thyroid
cancer varies worldwide. Most countries have reported an upward trend in its incidence.
Thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of
all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated
carcinoma (< 1%) and anaplastic carcinoma (< 2%).
Papillary thyroid carcinomas (PTCs) are the most commonly encountered thyroid
malignancies. The diagnosis of PTC is based on the special nuclear features such as
overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and
nuclear grooves. However, it is often difficult to differentiate PTC from benign
papillary thyroid hyperplasia . As differentiation between benign or malignant thyroid
lesions has clinical, therapeutic, and prognostic significance, it is necessary to make
accurate diagnosis by using biomarkers.
Recently, a large number of immunohistochemical (IHC) markers have been studied to assist
in differentiating non-neoplastic lesions from malignant thyroid lesions. CK19,
galectin-3, TG, Ki67, BRAF, calcitonin, HBME-1, TTF-1, and RET are some of the examples
of these IHC markers.
Galectin-3 is a 31-kDa β-galactoside binding lectin. It has been shown to be expressed by
several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell
adhesion and in cell-matrix interactions.
Criteria for eligibility:
Study pop:
Formalin fixed and paraffin embedded prostatic tissue blocks from 70 patients
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Thyroidectomy specimens both hemithyroidectomy and total thyroidectomy.
2. All the studied cases include sufficient materials for the immunohistochemical
study.
3. Complete clinical data
Exclusion Criteria:
1. Patients with recurrence of the primary tumor.
2. Patients with a history of preoperative chemotherapy and/or radiotherapy.
3. Insufficient or tiny tissue biopsies
Gender:
All
Minimum age:
20 Years
Maximum age:
90 Years
Start date:
March 2023
Completion date:
June 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05699590
